Ipsen Wins EU Approval for Ojemda in Pediatric Glioma

Paris, France – April 22, 2026

In a major breakthrough for pediatric oncology, Ipsen has announced that the European Commission has granted conditional approval for Ojemda® (tovorafenib), marking the first targeted therapy for relapsed or refractory pediatric low-grade glioma (pLGG) regardless of BRAF alteration status. This milestone represents a significant advancement in precision medicine for rare pediatric brain tumors, addressing a critical gap in treatment options for children affected by this life-altering disease.

First Targeted Therapy for Pediatric Low-Grade Glioma

The newly approved Ojemda introduces a novel mechanism of action as a Type II RAF kinase inhibitor, targeting abnormal BRAF signaling pathways that drive tumor growth. This approval applies to patients aged six months and older with relapsed or refractory pLGG, offering a much-needed alternative to traditional treatments such as surgery, chemotherapy, and radiotherapy, which often result in long-term neurological complications.

Pediatric Low-Grade Glioma is one of the most common childhood brain tumors, with over 800 new cases annually in Europe linked to BRAF alterations. Despite being classified as low-grade, the disease can lead to severe, lifelong impairments, including vision loss, motor dysfunction, and cognitive challenges, significantly impacting quality of life.

Ojemda’s approval marks a paradigm shift toward targeted, less invasive therapies, enabling clinicians to treat the underlying molecular drivers of the disease rather than relying solely on symptom management.

Strong Clinical Evidence from FIREFLY-1 Trial

The approval is supported by data from the Phase II FIREFLY-1 trial, which evaluated Ojemda in 137 pediatric and young adult patients with relapsed or refractory disease. The study demonstrated robust and durable tumor responses, with an overall response rate of up to 71% and a clinical benefit rate of 77%, highlighting the therapy’s strong efficacy profile.

Patients experienced rapid responses, with a median time to response of 5.4 months, and sustained benefits lasting up to 18 months, underscoring the treatment’s durability. Importantly, Ojemda showed a manageable safety profile, with most adverse events classified as mild to moderate, and a low treatment discontinuation rate.

Another key advantage is its once-weekly oral dosing, available in both tablet and liquid formulations, offering greater convenience and reduced treatment burden for pediatric patients and their families.

Transforming Pediatric Oncology and Future Outlook

The approval of Ojemda represents a critical step forward in addressing the unmet need in pediatric cancer treatment, an area historically underrepresented in drug development, with less than 10% of new therapies targeting pediatric diseases in recent years.

This therapy is also notable for being among the first medicines evaluated under the EU’s Joint Clinical Assessment (JCA) framework, streamlining regulatory processes and facilitating faster patient access across member states. Ipsen’s continued investment in oncology and rare diseases reflects a broader industry shift toward precision medicine and targeted therapies.

Ojemda is already approved in the United States under accelerated approval, and ongoing clinical trials, including Phase III FIREFLY-2, aim to expand its use into earlier lines of treatment. These developments position Ojemda as a cornerstone therapy in pediatric neuro-oncology, with the potential to improve long-term outcomes and reduce treatment-related complications.

As healthcare systems prioritize innovation in rare diseases, Ipsen’s latest approval underscores the growing importance of targeted biologics and personalized treatment approaches, offering new hope to children and families facing the challenges of pediatric brain tumors.

Source: Ipsen press release